Loeb Partners

Parachute Health, LLC is a New York-based company founded in 2015 that specializes in developing a technology platform for ordering durable medical equipment. This platform is designed to enhance patient care by facilitating the efficient coordination of medical equipment and supplies. It integrates seamlessly with electronic medical record systems, allowing healthcare providers to prescribe orders electronically. The platform offers features such as real-time order status updates, digitized signatures, and integrated messaging, which streamline operations and reduce the need for manual data entry. Additionally, it notifies clinicians about patients' insurance qualifications for equipment, thereby improving delivery times for discharged patients. Parachute Health caters to healthcare facilities, providers, and suppliers, aiming to minimize errors and enhance the overall ordering process for medical equipment.

Gravy Analytics, Inc. is a provider of location-based consumer intelligence, specializing in identifying consumer interests and affinities through verified attendance data at local events and activities. The company utilizes its proprietary AdmitOne™ technology to verify consumer visits to millions of locations and events, offering insights into consumer behavior that can enhance marketing strategies. Gravy Analytics provides a range of solutions, including targeting and customer retention tools, as well as a location-signal verification network. Founded in 2011 and based in Dulles, Virginia, Gravy Analytics was previously known as TimeRAZOR Inc. before rebranding in December 2013.

BetterPT is a platform technology company committed to transforming patient access and experience with healthcare services by providing end-to-end digital connectivity between physicians, physical therapists and patients. The company’s unique marketplace model, which includes interoperable, HIPAA compliant technology with EMR compatibility, enables patients greater access to physical therapy, an important and oftentimes overlooked part of clinical rehabilitation and preventive care. Partnering with the world leader in musculoskeletal health, the Hospital for Special Surgery (HSS), BetterPT has grown to support thousands of PT practices across the U.S., also offering a number of operational efficiencies and solutions to providers.

WaveMark, Inc. provides information products that enable hospitals and manufacturers to control and manage the flow of consumable medical devices. Its product enables to capture, store, and provide data via Web browser for manufacturers and hospitals. The company uses radio frequency identification technology to collect and report real time information in a hands free environment. WaveMark, Inc. was founded in 2003 and is based in Littleton, Massachusetts

Therion Biologics Corporation is focusing on the development and commercialization of innovative vaccines for the treatment of major cancers. Currently, Therion has two lead products moving into pivotal clinical trials in the next two years: PROSTVAC-VF for prostate cancer, developed by Therion, and ALVAC-CEA/B7.1, developed in collaboration with Aventis Pasteur Ltd., for colorectal cancer. The company also has a broad pipeline of vaccines in early clinical development for treatment of other major cancers, including breast cancer, lung cancer, melanoma and other solid tumors. Therion's partners include Aventis Pasteur, the National Cancer Institute and a network of leading clinical institutions around the world. Therion is a privately-held biotechnology company headquartered in Cambridge, Massachusetts. Therion's goal is to generate safe and effective therapeutic cancer vaccines that stimulate the immune system to specifically attack cancer cells, and thereby stabilize disease or induce tumor regression, improve patients' quality of life, and increase patient survival. While there has been significant progress in the treatment of some cancers, the prognosis for many cancer patients remains poor. For example, colorectal cancer affects an estimated 130,000 new patients and accounts for 56,300 deaths each year in the United States. Prostate cancer is the second leading cause of cancer death in men, with an estimated 180,400 new cases and 31,900 deaths in the U.S. annually. Recent advances in immunology and tumor biology have opened the door for the development of new generation therapeutic cancer vaccines. In particular, scientists now have a better understanding of the key molecular signals involved in eliciting potent and specific immune responses. This allows researchers to engineer vaccines that induce elements of the immune system required to eliminate cancer cells. Therion is at the forefront, quickly moving leading research into clinical development. Capitalizing on these recent scientific advances, Therion is targeting many of the major cancers currently lacking adequate treatment. Therion's therapeutic cancer vaccines for breast, lung, colorectal and prostate cancers, and melanoma address a majority of the large and rapidly growing market for cancer treatments.

Cubitz.com operates an online marketplace designed for the commercial real estate sector, facilitating the search for business space. The platform offers companies streamlined access to market information while ensuring user anonymity. For brokers, Cubitz.com enhances convenience and efficiency by minimizing lead-generation time without compromising proprietary information. This dual approach enables companies to make informed decisions regarding their real estate needs, fostering a more effective connection between businesses and available commercial spaces.